Story perspectives

COVID-19 Vaccines Boost Cancer Immunotherapy Survival Rates

10/29/2025

38 4

Summary

Story summary

A study published in Nature found that COVID-19 mRNA vaccines may boost the effectiveness of immune checkpoint inhibitors in cancer therapy.
In patients with advanced non-small cell lung cancer or melanoma who received an mRNA vaccine within 100 days of starting immunotherapy, median overall survival was 37.3 months versus 20.6 months for unvaccinated patients.
The study suggests vaccines may “warm up” cold tumors, increasing responsiveness to immune checkpoint inhibitors.

1 of 1

Story summary

A study published in Nature found that COVID-19 mRNA vaccines may boost the effectiveness of immune checkpoint inhibitors in cancer therapy.
In patients with advanced non-small cell lung cancer or melanoma who received an mRNA vaccine within 100 days of starting immunotherapy, median overall survival was 37.3 months versus 20.6 months for unvaccinated patients.
The study suggests vaccines may “warm up” cold tumors, increasing responsiveness to immune checkpoint inhibitors.